Ron Pruzan
About Ron Pruzan
Ron Pruzan serves as the Principal Scientist in the Department of Chemistry at Geron, where he has worked since 2010. He holds a B.S. with Distinction in Chemistry from the University of Illinois and a MSc and Ph.D. in Life Sciences from the Weizmann Institute of Science, with expertise in nucleic acid-based therapeutics.
Work at Geron
Ron Pruzan has been serving as the Principal Scientist in the Department of Chemistry at Geron since 2010. In this role, he focuses on developing cell-free assays for nucleic acid-based therapeutics. His tenure at Geron follows a previous position as a Senior Scientist from 1996 to 2004, where he contributed to various projects in the field of biochemistry and drug development. His extensive experience at Geron spans over 14 years, during which he has played a significant role in advancing the company's research initiatives.
Education and Expertise
Ron Pruzan holds a Bachelor of Science degree with Distinction in Chemistry from the University of Illinois. He furthered his education at the Weizmann Institute of Science, where he earned both an MSc and a Ph.D. in Life Sciences. His academic background provides a strong foundation for his expertise in protein purification, assay development, and nucleic acid enzymology. He is recognized for his work on nucleoside analogs and telomere attrition, as well as drug mechanism of action studies in oncology and virology.
Background
Before joining Geron, Ron Pruzan gained valuable experience as a Postdoctoral Fellow at Memorial Sloan-Kettering Cancer Center from 1986 to 1988. He also worked as a Visiting Scientist at Cold Spring Harbor Laboratory from 1994 to 1996. These positions allowed him to develop a robust understanding of cancer research and therapeutic development, which he has applied throughout his career in various scientific roles.
Achievements
Throughout his career, Ron Pruzan has made significant contributions to the field of biochemistry and drug development. His work in developing cell-free assays and his expertise in nucleic acid-based therapeutics have advanced research in these areas. He actively engages in science education, sharing his knowledge and expertise in biochemistry and related fields, thereby contributing to the training of future scientists.